BlueRock Therapeutics

Home
United States
Cambridge, MA
BlueRock Therapeutics

Directions Website

Striving to transform the treatment of disease by harnessing the power of cell therapy

10/14/2026

Ever have a word right on the tip of your tongue and it just won't come out?

For people with Parkinson's, this "tip-of-the-tongue" feeling is common, and a softer voice can make it even more frustrating when you have to repeat yourself.

The Cognitive Symptoms chapter of our free Every Victory Counts® manual has practical ways to navigate these changes. Get your copy at dpf.org/evc.

We're grateful to Genentech, Amneal Pharmaceuticals, BlueRock Therapeutics, AbbVie, and The Michael J. Fox Foundation for Parkinson's Research for supporting the Every Victory Counts® manual and helping make this resource available to the Parkinson's community.

10/13/2026

BlueRock is pleased to sponsor the The Michael J. Fox Foundation for Parkinson's Research's PDIQ+ You Series, which concludes it's 2026 series in Washington DC on October 24. BlueRock will be in attendance - stop by and say hello!

10/08/2026

World Sight Day, observed annually on the second Thursday of October, is a global event with the aim of drawing attention to blindness and vision impairment. It was originally initiated by the SightFirstCampaign of Lions Clubs International Foundation in 2000 and has since been adopted by IABP and WHO.

BlueRockers are partnering with Lions Clubs International for the 3rd year to run a glasses drive across all of our locations.

09/30/2026

Together with Bayer, today we are announcing that lemiretprocel (OpCT-001), our investigational iPSC-derived therapy for primary photoreceptor diseases, has received Orphan Drug Designation from the U.S. FDA and the EU EMA. U.S. FDA designations are for treating retinitis pigmentosa and cone-rod dystrophy. EU EMA designations are for treating both syndromic and non-syndromic IRDs of the rod-dominant phenotype and non-syndromic IRDs of the cone-dominant phenotype.

Read the full press release:

BlueRock Therapeutics announced that its investigational cell therapy, lemiretprocel (OpCT-001), has received Orphan Drug Designations from the U.S. FDA and the EU EMA. US FDA designations are for treating retinitis pigmentosa and cone-rod dystrophy. EU EMA designations are for treating both syndrom...

09/22/2026

We were honored to participate in this year’s Parkinson Canada SuperWalk and proud to share that Team BlueRock, along with families and friends, raised more than $15,000 for Parkinson Canada.

Thank you to everyone who donated, walked, and showed their support. We are inspired every day by the Parkinson’s community and remain committed to advancing innovation and helping create a brighter future for patients and families.

09/14/2026

Team BlueRock returned for our 8th year as lead sponsor of the New England Parkinson's Ride this past Saturday in Old Orchard Beach, Maine! We are proud to have tripled our donation goal, fundraising over $30,000 in support of the The Michael J. Fox Foundation for Parkinson's Research

For over a decade, the NE Parkinson’s Ride has been the country’s largest independent single-day fundraising event in support of the Michael J. Fox Foundation and their mission to help deliver the next generation of treatments for Parkinson’s disease. And what a beautiful day it was!

08/12/2026

BlueRock is pleased to sponsor the The Michael J. Fox Foundation for Parkinson's Research PDIQ+ You Series, which continues in St. Louis on August 15. BlueRock will be in attendance - stop by and say hello!

Join us in St. Louis for our free educational event designed for people with Parkinson’s and their loved ones. This in-person event features sessions on navigating Parkinson’s, managing care, and the latest research. The accompanying Parter Expo includes information on treatment options and loca...

07/15/2026

We are harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Learn more at www.bluerocktx.com

07/15/2026

Are clinical trials right for you? Learn more with a webinar by The Michael J. Fox Foundation for Parkinson's Research sponsored by BlueRock.

07/15/2026

Parkinson's treatment has had few advancements in 60 years. Now, cell therapy clinical trials aim to replace the neurons that are lost. Click the link below to learn more about the potential of cell therapy for Parkinson's disease.

Address

238 Main Street
Cambridge, MA
02142

Website

http://bluerocktx.com/

Alerts

Be the first to know and let us send you an email when BlueRock Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.